Low-dose cytarabine as a treatment of choice for a patient with primary myelofibrosis in the post-splenectomy phase
Harutyunyan L.,1,2 Meliksetyan K.,1,2 Oganesyan A.,3 Oseyan H.,1,2 Khachatryan H.,1,2 Hakobyan Ye.1-3
1 Yolyan Hematological Center, Yerevan, Armenia
2 Armenian Hematological Association, Yerevan, Armenia
3 Department of Hematology and Transfusion Medicine, Avdalbekyan National Institute of Health, Yerevan, Armenia
ABSTRACT
Primary myelofibrosis (PMF) is a hematologic malignancy belonging to Ph-negative myeloproliferative neoplasms, and it is commonly characterized by a higher risk of acute myeloid leukemia transformation. The aim of this case report is a demonstration of treatment with lowdose cytarabine for a non-transformed newly diagnosed PMF patient with no indication for oral therapy due to post-splenectomy complications.
Keywords: myelofibrosis, splenectomy, thrombosis, cytarabine, treatment